This company listing is no longer active
2K7 Stock Overview
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TCR2 Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.49 |
| 52 Week High | US$6.05 |
| 52 Week Low | US$2.49 |
| Beta | 1.78 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2K7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -1.2% |
| 1Y | n/a | -15.4% | 1.2% |
Return vs Industry: Insufficient data to determine how 2K7 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2K7 performed against the German Market.
Price Volatility
| 2K7 volatility | |
|---|---|
| 2K7 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2K7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2K7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 139 | Garry Menzel | www.tcr2.com |
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company’s lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma.
TCR2 Therapeutics Inc. Fundamentals Summary
| 2K7 fundamental statistics | |
|---|---|
| Market cap | €95.44m |
| Earnings (TTM) | -€115.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs 2K7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2K7 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$114.71m |
| Earnings | -US$114.71m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2K7 perform over the long term?
See historical performance and comparison